Abstract |
Six patients with fluctuating Parkinson's disease received single rising oral doses of the nonergot dopamine agonist CV 205-502 in an open experimental study. Doses of 0.5 mg produced antiparkinsonian effects of comparable intensity but longer duration than 200 mg of L-DOPA. CV 205-502, which combines structural features common to both ergolines and apomorphine, thus revealed interesting antiparkinsonian properties, but nausea and vomiting were dose-limiting side effects in all patients tested.
|
Authors | W Poewe, G Luef, B Kleedorfer, M Emre |
Journal | Movement disorders : official journal of the Movement Disorder Society
(Mov Disord)
Vol. 5
Issue 3
Pg. 257-9
( 1990)
ISSN: 0885-3185 [Print] United States |
PMID | 2388646
(Publication Type: Journal Article)
|
Chemical References |
- Aminoquinolines
- Receptors, Dopamine
- quinagolide
|
Topics |
- Administration, Oral
- Aged
- Aminoquinolines
(therapeutic use)
- Dose-Response Relationship, Drug
- Female
- Humans
- Male
- Middle Aged
- Parkinson Disease, Secondary
(drug therapy)
- Receptors, Dopamine
(drug effects)
|